American Diabetes Congress Report 2017 (4)
San Diego, USA, 10-Jun-17
New Learnings from the Results of the Liraglutide Effect and Action in Diabetes – Evaluation of Cardiovascular Outcome Results (LEADER) Trial
Deacon, MD C.F.
What’s New in Insulin-Related Therapy?
Home, Prof. P.
Effects of New Diabetic Treatments on Diabetic Kidney Disease
Tuomilehto, Prof. J.
Cardiovascular Safety of Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) Trial Results
Sattar, Prof. Dr. N.
Poster Session: News on SGLT2-Inhibitors
Del Prato, Prof. S.
Supported by Boehringer Ingelheim Pharma GmbH & Co. KG